TAXIS Pharmaceuticals is focused on developing innovative therapies to combat antimicrobial resistance (AMR) by targeting the fundamental mechanisms that allow bacteria to survive and thrive despite antibiotic treatments. Their lead investigational therapeutic, TXA709, is an oral anti-MRSA agent that disrupts bacterial cell walls and has shown promise in Phase I trials without serious adverse events. Additionally, the company is exploring efflux pump inhibitors (EPIs) designed to enhance the efficacy of existing antibiotics by preventing multidrug-resistant bacteria from expelling these drugs. This approach aims to address critical infections, such as hospital-acquired pneumonia, and has garnered significant funding to support ongoing research and development.

In addition to TXA709 and EPIs, TAXIS Pharmaceuticals is also investigating dihydrofolate reductase inhibitors (DHFRIs) that target essential bacterial enzymes to hinder cell proliferation, particularly in the treatment of highly resistant gonorrhea. The company is committed to expanding its pipeline with new classes of anti-resistance agents that utilize novel mechanisms of action, thereby addressing the growing threat of AMR across various infectious diseases. Through these advanced therapeutic strategies, TAXIS Pharmaceuticals envisions a future where antimicrobial resistance is significantly reduced, ultimately improving patient outcomes and public health.

United States

TAXIS Pharmaceuticals is a biotech company devoted to combatting the serious and deadly societal threat of antibiotic resistance by creating therapies that address the root cause of the issue. 

We're developing therapies that, when used in combination with FDA-approved antibiotics, are intended to restore the efficacy of those medications. We currently have one investigational therapy that has completed Ph1 human trials, and several additional products in the pipeline. 

TAXIS Pharmaceuticals

Company Details